Agios Pharmaceutical (AGIO) 42.75 $AGIO Flagship

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 4:05 AM

Agios Pharmaceutical (AGIO) 42.75 $AGIO

Flagship Ventures Names Daniel McIntyre Partner
PR Newswire - Wed Jun 29, 3:47PM CDT
Flagship Ventures today announced the appointment of Daniel McIntyre to the position of Partner, Strategic Communication. In this new role, he is responsible for communication for Flagship's growing organization as well as for its expanding ecosystem of internally generated start-up companies.
EDIT: 25.32 (-0.30), TTOO: 5.32 (-2.29), AGIO: 42.75 (+0.12), MCRB: 29.99 (unch)

Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 36.12 (+0.35), RTRX: 18.65 (+0.35), AGIO: 42.75 (+0.12), BMY: 75.28 (+1.20)

Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
GlobeNewswire - Thu Jun 09, 8:21AM CDT
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -
AGIO: 42.75 (+0.12)

What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.58 (+0.07), INSY: 15.66 (+0.33), AGIO: 42.75 (+0.12), GNCA: 4.45 (+0.11)

Agios to Host Conference Call from the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 01, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 2016 at 9:30 a.m. ET to discuss clinical and preclinical data presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
AGIO: 42.75 (+0.12)

Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:01AM CDT
Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 42.75 (+0.12)

Agios Strikes Metabolic Immuno-Oncology Deal with Celgene
Zacks Equity Research - Zacks Investment Research - Wed May 18, 10:00AM CDT
Agios Pharmaceuticals (AGIO) inked a metabolic immuno-oncology agreement with Celgene; Agios gained global rights to AG-120 and updated 2016 view.
ANIP: 56.51 (-1.61), RTRX: 18.65 (+0.35), AGIO: 42.75 (+0.12), CELG: 105.03 (+0.62)

Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
GlobeNewswire - Tue May 17, 3:01PM CDT
- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment -
AGIO: 42.75 (+0.12), CELG: 105.03 (+0.62), CELGZ: 1.43 (+0.08)

Agios (AGIO) Q1 Loss Lower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:51AM CDT
Agios Pharmaceuticals (AGIO) reported a first-quarter 2016 loss of 61 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 69 cents.
ANIP: 56.51 (-1.61), RTRX: 18.65 (+0.35), AGIO: 42.75 (+0.12), CELG: 105.03 (+0.62)

Agios Pharmaceuticals reports 1Q loss
Automated Insights - Thu May 05, 2:45PM CDT
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $23.2 million in its first quarter.
AGIO: 42.75 (+0.12)

Agios Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 6:01AM CDT
Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 42.75 (+0.12)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 41.89 (+0.53), BIIB: 251.30 (+4.03), CNAT: 2.19 (unch), AMGN: 161.10 (+4.51), RPRX: 1.73 (+0.05), JNJ: 122.85 (+0.34), GILD: 86.55 (+1.08), GWPH: 94.83 (+1.36), GERN: 2.72 (+0.03), AVEO: 0.95 (+0.02), ICPT: 151.73 (+7.98), AGIO: 42.75 (+0.12), NVS: 82.13 (+0.33)

What's in Store for Agios (AGIO) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:38PM CDT
Agios Pharmaceuticals (AGIO), which is set to report first-quarter 2016 results on May 5, delivered a negative surprise of 300% last quarter.
IPXL: 29.35 (+0.23), JAZZ: 139.88 (+1.40), AGIO: 42.75 (+0.12), CELG: 105.03 (+0.62)

Agios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Mon May 02, 7:30AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, May 5, 2016 at 8:30 a.m. ET to report its first quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 42.75 (+0.12)

Mylan (MYL) Q1 Earnings: What's in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 6:20AM CDT
Mylan (MYL), which is set to report first-quarter 2016 results on May 3, delivered a negative earnings surprise of 2.40% in the last quarter.
MYL: 44.54 (+0.84), AGIO: 42.75 (+0.12), GNCA: 4.45 (+0.11), SNY: 40.85 (-0.14)

Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 6:06PM CDT
Merrimack (MACK) will report first-quarter 2016 earnings on May 2 after the market closes.
ZTS: 48.50 (+0.81), MACK: 5.62 (unch), AGIO: 42.75 (+0.12), LLY: 79.66 (+0.34)

Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 48.50 (+0.81), AGIO: 42.75 (+0.12), PRTA: 44.01 (+2.28)

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA(R) (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy
GlobeNewswire - Wed Mar 30, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1/2, multicenter, international, open-label study, sponsored by Celgene Corporation, of AG-221 or AG-120 in combination with VIDAZA (azacitidine for injection) in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are not eligible for intensive chemotherapy. AG-221 and AG-120 are first-in-class, oral, selective, potent inhibitors of mutant IDH2 and IDH1, respectively, and are being developed in collaboration with Celgene.
AGIO: 42.75 (+0.12)

The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 06, 6:32AM CST
What: Shares of Agios Pharmaceuticals , a clinical-stage drug developer primarily focused on researching cancer and rare-disease treatments, were hammered in January, falling 35% based on data from S&P Capital IQ . The primary culprit behind...
AGIO: 42.75 (+0.12), CELG: 105.03 (+0.62)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LCMC Health, Helix Collaborate for Genomics Future

What’s the Big Deal with Genomics? It's not every day you hear about a healthcare initiative aimed at making significant strides in genomics, and right in Louisiana’s backyard no less. LCMC Health has teamed up with Helix in a project that plans to involve 100,000 individuals. That’s a big number in research circles, indicating serious intent to redraw some...

Robotic Tiling Deal Boosts Foley Tile's National Reach

Robots Changing the Tiling Game Human Friendly Robotics (HFR) just dropped a game-changer—a $3.55 million deal with Foley Tile that's shaking up the tiling scene. For folks not glued to the market, this means HFR's Tyler robots are now neck-deep in Arizona soil, tasked with tiling jobs that once had the Foley crew running ragged. The Motherload of Opportunities Jerry...

Rising Rates and War in Iran Hit Investor Nerves

An Unsettling Mix for Real Estate Investors The latest RCN Capital Investor Sentiment Survey reveals a shaky real estate landscape, plagued by a mix of geopolitical conflict and central bank policy changes. You know you're in trouble when investor sentiment just crawls back from an all-time low, bouncing barely from an index score of 84 to 89. It's the kind of timid...

LifeWave's Bold New Path in Human Performance

Redefining the Everyday Athlete Not every day you see a wellness company talking about 'performance' in the broader human sense. Not just for the pros or those beating personal records but for anyone looking to lift the quality of their daily grind. That's the new line LifeWave's drawing in the sand with their spiffy 'Human Performance Technology.' They're looking to...

Procede Software Acquires RIMSS: Dealer Tech Shift?

Procede's Big Play Seems like Procede Software is tossing the dice with its latest move. The software scene for dealership management is as cutthroat as a New York deli lineup, and now we've got Procede moving to scoop up RIMSS. This isn't just a back-office shuffle; it's a world-rocking maneuver that brings decades of dealer technology know-how into one basket. What's...

Prepare Denver Sprinkler Systems Before Winter Strikes

Colorado's Unpredictable Weather: Don't Get Caught Cold The leaves turning color might be the signal of fall, but in Colorado, the weather seems to have a mind of its own—sunny one moment, bone-chilling the next. Denver homeowners, it's time to take a hard look at your outdoor sprinkler systems. Why? Because those freezing nights can sneak up faster than you'd think and...

Investar Rides Acquisition Wave in Strong Q3 2026

Third Quarter Shakeup: Unpacking The Numbers Fresh off some impactful strategic moves, Investar Holding Corporation's third-quarter results for 2026 are showing some serious upward momentum. Net income sitting at $11.1 million, up from $8.9 million just a quarter earlier, is a marked improvement in anyone's book, especially when you rewind to the $5.7 million a year...

When Families Should Consider Life Insurance Plans

Let’s talk about why life insurance isn’t just for those walking around with gray hair. K.D. the Insurance Queen from Centennial, Colorado, dishes out the clearest advice on when and why families ought to have it in their arsenal. A New Mindset on Life Insurance Some folks out there think life insurance is something you ponder in your twilight years. But here’s the...

Middle East's Premier Jewellery Event: A Game-Changer

An Event Gemmed with Strategic Importance The Middle East is about to see its streets glitter even more than usual. Next week, the Jewellery, Gem & Technology in Dubai (JGTD) event rolls into town, packed with brands that’ll drop in like swanky diamonds. We’re talking 300 heavy-duty exhibitors from all corners of the globe, ready to strut their stuff at the DEC Expo...

HYXI Eyes European Growth with Product Matrix Launch

Unveiling the Future: HYXI's Grand Showcase You know you're onto something big when nearly 60 industry insiders travel halfway across the globe to see what you've got cooking. That's exactly what went down at HYXI's Hangzhou headquarters on October 21, 2026. Under a snazzy theme, "See Where It Begins, Shape the Future," this European Partner Day was more than just a...